Xilio Therapeutics, Inc. (XLO)

1.0800 +0.0400 (+3.85%) At close: 04:00PM EDT

Xilio Therapeutics, Inc.

828 Winter Street
Suite 300
Waltham, MA 02451
United States
857 524 2466
https://xiliotx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 73

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Rene Russo BCPS, Pharm.D.	President, CEO & Director	875.13k	N/A	1975
Mr. Christopher Frankenfield	Chief Operating Officer	704.85k	N/A	1982
Dr. Katarina Luptakova M.D.	Chief Medical Officer	591.92k	N/A	1976
Mr. Kevin M. Brennan	Senior VP of Finance & Accounting	N/A	N/A	1970
Dr. Uli Bialucha Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Ms. Stacey J. Davis	Chief Business Officer	N/A	N/A	N/A
Dr. Scott Coleman Ph.D.	Chief Development Officer	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors. The company also develops cytokine programs, which comprises XTX202, a tumor-activated IL-2; and XTX301, an investigational tumor-activated, engineered IL-12 molecule. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.

Corporate governance

Xilio Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.